Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  title={Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.},
  author={Howard A. Burris and Malcolm J. Moore and John S. Andersen and M R Green and Mace L. Rothenberg and Manuel R. Modiano and M. Christine Cripps and Russell K. Portenoy and Anna Maria V. Storniolo and Peter G. Tarassoff and Robert L. Nelson and F. Andrew Dorr and Christine Stephens and Daniel D. Von Hoff},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={15 6},
  • H. Burris, M. Moore, D. V. Von Hoff
  • Published 1 June 1997
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. [] Key Method The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (> or = 4 weeks) improvement in at least one parameter without worsening in any others.

Figures and Tables from this paper

Gemcitabine in advanced pancreatic cancer: a phase II trial.

It is concluded that gemcitabine chemotherapy was very well tolerated and determined a significant clinical improvement with modest antitumoral activity in patients with advanced pancreatic cancer.

Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.

The treatment efficacy, toxicity and prognostic factors of single-agent gemcitabine in Japanese patients with advanced pancreatic cancer are comparable to those that have been reported in Western patients.

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma

This schedule demonstrates that weekly therapy with paclitaxel after pretreatment can be effective with a low toxicity profile, which opens up an additional therapeutic option for a selected patient group with a poor prognosis so far.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Docetaxel seems to have mild activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer, and other dosing regimens and novel taxanes such as Nab-paclitaxel should be explored in this setting.

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer

Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.

Gemcitabine in Advanced Pancreatic Cancer: A Phase II Trial

Treatment of Metastatic Pancreatic Cancer with a Combination of Gemcitabine and 5-Fluorouracil: A Single Center Phase II Study

The weekly administration of gemcitabine combined with 5-fluorouracil bolus iv is an active and well-tolerated regimen in metastatic pancreatic cancer, however, its efficacy is relatively limited.

S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.

S-1 monotherapy is marginally effective and well tolerated in the second-line setting in patients with gemcitabine-refractory advanced pancreatic cancer.

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

Combination chemotherapy of S-1 plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.




Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.

Despite promising results in patients with advanced colorectal cancer, this dose schedule of5-FU and leucovorin does not appear to be superior to 5-FU alone for the treatment of advanced pancreatic cancer.

Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine.

The combination of cisplatin, ARA-C, and caffeine is an active and tolerable regimen in the treatment of advanced pancreatic cancer and is being compared with standard therapy is in progress.

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.

This combination of leucovorin and 5-FU did not demonstrate meaningful therapeutic activity in patients with adenocarcinoma of the pancreas and was associated with moderate to severe toxicity, and should not be considered a standard treatment for patients with this disease.

A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

The most favorable regimen was 5‐FU with low‐dose leucovorin, based upon considerations of therapeutic effectiveness, toxicity, and cost, in the treatment of advanced colorectal cancer.

A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5‐fluorouracil, doxorubicin, and cisplatin

Neither the Mallinson regimen nor FAP can be recommended as therapy for advanced pancreatic carcinoma and any chemotherapy for this disease should remain an experimental endeavor.

A phase III comparison trial of streptozotocin, mitomycin, and 5‐fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

In this Phase III comparison, CAC was not superior to conventional therapy with SMF in terms of response and was inferior for survival, and neither regimen is effective treatment for advanced PC.

Randomized study of 5‐FU and ccnu in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group

There was no evidence of a beneficial effect on survival from drug treatment in the group as a whole or in any subgroup analyzed.

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

Intensive-course 5FU plus low-dose leucovorin appears to have a superior therapeutic index compared with weekly 5FUplus high-doseLeucovOrin using the dosage administration schedules applied in this study based on similar therapeutic effectiveness, but lower financial cost, and less need for hospitalization to manage chemotherapy toxicity.

Treatment of cancer with weekly intravenous 5‐fluorouracil

Patients with disseminated cancer were treated weekly with 5‐fluorouracil by rapid intravenous injection, beginning at 15 mg/kg/wk for 1 month, increased to 20 mg/ kg/wk (if necessary) to levels producing mild toxicity or an antitumor effect, which enabled patients to be treated safely on an ambulatory basis.

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

Because of a failure to produce improved survival or palliation, unrewarded toxicity, and excessive cost, neither the FA nor FAM regimen can be recommended for the treatment of advanced pancreatic or gastric cancer.